Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of repaglinide plus metformin as initial treatment compared to repaglinide alone in Chinese subjects with type 2 diabetes having an HbA1c (glycosylated haemoglobin A1c) over 8.5 % and who never have taken oral sugar-lowering drugs before. The associated unfavourable events including low blood sugar episodes between the two treatments are also compared.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2; Diabetes
• Intervention / Treatment: Drug: repaglinide; Drug: metformin; Drug: repaglinide

• Study Type: Interventional
• Enrollment (Actual): 433
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Hangzhou, China, 310016
    • Novo Nordisk Investigational Site
  • Nantong, China, 226001
    • Novo Nordisk Investigational Site
  • Shanghai, China, 200040
    • Novo Nordisk Investigational Site
  • Fujian
    • Fuzhou, Fujian, China, 350001
      • Novo Nordisk Investigational Site
  • Jiangsu
    • Nanjing, Jiangsu, China, 210012
      • Novo Nordisk Investigational Site
    • Nanjing, Jiangsu, China, 210029
      • Novo Nordisk Investigational Site
    • Nanjing, Jiangsu, China, 210009
      • Novo Nordisk Investigational Site
    • Suzhou, Jiangsu, China, 215004
      • Novo Nordisk Investigational Site
    • Wuxi, Jiangsu, China, 214023
      • Novo Nordisk Investigational Site
  • Jiangxi
    • Nanchang, Jiangxi, China, 330006
      • Novo Nordisk Investigational Site
  • Shanghai
    • Shanghai, Shanghai, China, 200072
      • Novo Nordisk Investigational Site
    • Shanghai, Shanghai, China, 200120
      • Novo Nordisk Investigational Site
    • Shanghai, Shanghai, China, 200092
      • Novo Nordisk Investigational Site
    • Shanghai, Shanghai, China, 200025
      • Novo Nordisk Investigational Site
    • Shanghai, Shanghai, China, 200001
      • Novo Nordisk Investigational Site
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310003
      • Novo Nordisk Investigational Site
    • Wenzhou, Zhejiang, China, 325000
      • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosed with type 2 diabetes
• Never taken oral antidiabetic drugs before
• HbA1c greater than 8.5 %
• BMI (Body Mass Index) less than or equal to 35 kg/m^2

Exclusion Criteria:

• Known or suspected allergy to repaglinide, metformin, or any of the excipients in the medications
• Taken an investigational drug in another clinical trial within 4 weeks prior to this trial
• Impaired liver function, defined as ASAT (aspartate aminotransferase) or ALAT (alanine aminotransferase) equal to or greater than 2 times upper normal limit
• Have a clinically significant, active disease of the gastrointestinal, pulmonary, neurological, renal, genitourinary, and haematological systems
• Severe uncontrolled or untreated hypertension (sitting diastolic blood pressure (BP) equal to or greater than 100 mmHg or systolic BP equal to or greater than 180 mmHg)
• Impaired renal function
• Acute or chronic acidosis or if there are plans to have a radiographic material containing iodine
• Have a clinically significant, active cardiovascular disease, or decompensated heart failure
• Treatment with systemic corticosteroids within the past two months prior to screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Repaglinide + metformin; Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.	Drug: repaglinide; The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily; Drug: metformin; The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily; Drug: repaglinide; The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
Active Comparator: Repaglinide; Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.	Drug: repaglinide; The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily; Drug: repaglinide; The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Glycosylated Haemoglobin A1c (HbA1c)	Calculated as an estimate of the mean change in HbA1c after 16 weeks of treatment.	week -2 (screening), week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Fasting Plasma Glucose	Calculated as an estimate of the mean change in fasting plasma glucose after 16 weeks of treatment.	week 0, week 16
Change in 2-hour Postprandial Plasma Glucose	Calculated as an estimate of the mean change in 2-hour postprandial plasma glucose following a standard test meal after 16 weeks of treatment	Week 0, week 16
Change in 7-point Plasma Glucose Profile	Calculated as an estimate of the mean change in 7-point (before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, bedtime) plasma glucose profile after 16 weeks of treatment.	Week 0, week 16
Change in Fasting Serum Insulin	Calculated as an estimate of the mean change in fasting serum insulin after 16 weeks of treatment.	Week 0, week 16
Change in 2-hour Postprandial Serum Insulin	Calculated as an estimate of the mean change in 2-hour postprandial serum insulin after 16 weeks of treatment.	Week 0, week 16
Change in Fasting Serum C-peptide	Calculated as an estimate of the mean change in fasting serum C-peptide after 16 weeks of treatment	Week 0, week 16
Change in 2-hour Postprandial Serum C-peptide	Calculated as an estimate of the mean change in 2-hour postprandial serum C-peptide after 16 weeks of treatment	Week 0, week 16
Hypoglycaemic Episodes	Number of hypoglycaemic episodes from Week 0 to Week 16, defined as major, minor or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.	Weeks 0-16
Change in Blood Pressure	Calculated as the mean change in diastolic and systolic blood pressure after 16 weeks of treatment	Week 0, week 16
Physical Examinations	The number of subjects having a physical examination event that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. Physical examination included cardiovascular system, respiratory system, musculoskeletal system, nervous system and abdomen.	Week -2, week 16
ECG (ElectroCardioGram)	The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.	Week -2, week 16
Biochemistry: Alanine Aminotransferase (ALAT)	The number of subjects having a change in Alanine Aminotransferase (ALAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.	Week -2, week 16
Biochemistry: Alanine Aminotransferase (ASAT)	The number of subjects having a change in Aspartate Aminotransferase (ASAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.	Week -2, week 16
Haematology: Haemoglobin	Haemoglobin was measured. The number of subjects having a change in Haemoglobin measurement from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant' 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.	Week -2, week 16

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Publications and helpful links

General Publications

• Wang W, Bu R, Su Q, Liu J, Ning G. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. Expert Opin Pharmacother. 2011 Dec;12(18):2791-9. doi: 10.1517/14656566.2011.602341. Epub 2011 Jul 22.

Helpful Links

• Clinical Trials at Novo Nordisk

Study record dates

Study Major Dates

• Study Start: February 1, 2009
• Primary Completion (Actual): November 1, 2009
• Study Completion (Actual): November 1, 2009

Study Registration Dates

• First Submitted: January 8, 2009
• First Submitted That Met QC Criteria: January 8, 2009
• First Posted (Estimate): January 9, 2009

Study Record Updates

• Last Update Posted (Actual): February 10, 2017
• Last Update Submitted That Met QC Criteria: December 19, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Metformin; Repaglinide
• Other Study ID Numbers: AGEE-3705